Docking

Topics: Dopamine receptor, Receptor antagonist, Agonist Pages: 27 (9135 words) Published: January 17, 2013
Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation Chiara Bianca Maria Platania, Salvatore Salomone, Gian Marco Leggio, Filippo Drago, Claudio Bucolo* Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, Catania University, Catania, Italy

Abstract
Dopamine (DA) receptors, a class of G-protein coupled receptors (GPCRs), have been targeted for drug development for the treatment of neurological, psychiatric and ocular disorders. The lack of structural information about GPCRs and their ligand complexes has prompted the development of homology models of these proteins aimed at structure-based drug design. Crystal structure of human dopamine D3 (hD3) receptor has been recently solved. Based on the hD3 receptor crystal structure we generated dopamine D2 and D3 receptor models and refined them with molecular dynamics (MD) protocol. Refined structures, obtained from the MD simulations in membrane environment, were subsequently used in molecular docking studies in order to investigate potential sites of interaction. The structure of hD3 and hD2L receptors was differentiated by means of MD simulations and D3 selective ligands were discriminated, in terms of binding energy, by docking calculation. Robust correlation of computed and experimental Ki was obtained for hD3 and hD2L receptor ligands. In conclusion, the present computational approach seems suitable to build and refine structure models of homologous dopamine receptors that may be of value for structure-based drug discovery of selective dopaminergic ligands. Citation: Platania CBM, Salomone S, Leggio GM, Drago F, Bucolo C (2012) Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation. PLoS ONE 7(9): e44316. doi:10.1371/journal.pone.0044316 Editor: Yang Zhang, University of Michigan, United States of America Received May 25, 2012; Accepted August 1, 2012; Published September 6, 2012 Copyright: ß 2012 Platania et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported in part by a National grant PON01-00110. Dr. Chiara B. M. Platania was supported by the International Ph.D. Program in Neuropharmacology, University of Catania, Italy. The authors wish to thank the ‘‘Consorzio Cometa’’ [http://www.consorzio-cometa.it/] for the computational hours. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: claudio.bucolo@unict.it

Introduction
The dopaminergic systems in the central nervous system (CNS) have been extensively studied over the past 50 years [1]. Dopamine exerts its action through five distinct G-protein coupled receptors (D1–5 receptors), grouped in two classes, D1-like and D2like receptors, that differ in their signal transduction, binding profile and physiological effects [1]. D1-like receptors (D1 and D5) are principally coupled to stimulatory Gs-proteins and enhance the activity of adenylyl cyclase (AC), whereas D2-like receptors (D2, D3, and D4) are primarily coupled to inhibitory Gi-proteins and suppress the activity of AC [1]. Alternative splicing of D2 receptor mRNA leads to generation of two isoforms: D2 short (D2S) and D2 long (D2L), which have been associated (though not exclusively) with presynaptic and postsynaptic populations of D2 receptors, respectively [2]. The difference between these two splicing isoforms is represented by 29 amino acid residues in the III intracellular loop (3ICL), involved in the G protein coupling. The D2S is mainly considered as a presynaptic receptor, whereas, the D2L as a postsynaptic receptor [2], like the D3 [3]....

References: 1. Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological reviews 63: 182–217. 2. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, et al. (2003) Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci U S A 100: 4305–4309. 3. Landwehrmeyer B, Mengod G, Palacios JM (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 18: 187– 192. 4. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, et al. (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20: 8677–8684. 5. Chen PC, Lao CL, Chen JC (2009) The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. J Neurochem 110: 1180–1190. 6. Ballesteros JA, Shi L, Javitch JA (2001) Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 60: 1–19. 7. Neve KA, Seamans JK, Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165–205. 8. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, et al. (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5: 25–43. 9. Potter DE, Ogidigben MJ, Chu TC (1998) Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. Pharmacology 57: 249–260. 10. Ogidigben M, Chu TC, Potter DE (1993) Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine. The Journal of pharmacology and experimental therapeutics 267: 822–827. 11. Potter DE, Shumate DJ (1987) Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function. Journal of ocular pharmacology 3: 309–321. 12. Mekki QA, Hassan SM, Turner P (1983) Bromocriptine lowers intraocular pressure without affecting blood pressure. Lancet 1: 1250–1251. 13. Geyer O, Robinson D, Lazar M (1987) Hypotensive effect of bromocriptine in glaucomatous eyes. Journal of ocular pharmacology 3: 291–294. 14. Chu E, Chu TC, Potter DE (2000) Mechanisms and sites of ocular action of 7hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist. J Pharmacol Exp Ther 293: 710–716. 15. Bucolo C, Leggio GM, Maltese A, Castorina A, D’Agata V, et al. (2011) Dopamine-3 receptor modulates intraocular pressure: implications for glaucoma. Biochem Pharmacol 83: 680–686. 16. Sibley DR, Monsma FJ Jr (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13: 61–69. 17. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49: 231–252. 18. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151. 19. Shi L, Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42: 437–467. 20. Malmberg A, Nordvall G, Johansson AM, Mohell N, Hacksell U (1994) Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors. Mol Pharmacol 46: 299–312. 21. Chumpradit S, Kung MP, Kung HF (1993) Synthesis and optical resolution of (R)- and (S)-trans-7-Hydroxy-2-[N-propyl-N-(39-iodo-29-propenyl)amino]tetralin: a new D3 dopamine receptor ligand. J Med Chem 36: 4308–4312. 22. Chumpradit S, Kung MP, Vessotskie J, Foulon C, Mu M, et al. (1994) Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem 37: 4245–4250. 23. Martin PL, Kelly M, Cusack NJ (1993) (-)-2-(N-propyl-N-2-thienylethylamino)5-hydroxytetralin (N-0923), a selective D2 dopamine receptor agonist demonstrates the presence of D2 dopamine receptors in the mouse vas deferens but not in the rat vas deferens. J Pharmacol Exp Ther 267: 1342–1348. 24. Reynolds NA, Wellington K, Easthope SE (2005) Rotigotine: in Parkinson’s disease. CNS drugs 19: 973–981. 25. Glase SA, Corbin AE, Pugsley TA, Heffner TG, Wise LD (1995) Synthesis and dopaminergic activity of pyridine analogs of 5-hydroxy-2-(di-n-propylamino)tetralin. J Med Chem 38: 3132–3137. 26. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, et al. (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290: 29–36. 27. Bettinetti L, Schlotter K, Hubner H, Gmeiner P (2002) Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J Med Chem 45: 4594–4597. 28. Lopez L, Selent J, Ortega R, Masaguer CF, Dominguez E, et al. (2010) Synthesis, 3D-QSAR, and structural modeling of benzolactam derivatives with binding affinity for the D(2) and D(3) receptors. ChemMedChem 5: 1300–1317. 29. Ortega R, Hubner H, Gmeiner P, Masaguer CF (2011) Aromatic ring functionalization of benzolactam derivatives: new potent dopamine D3 receptor ligands. Bioorganic & medicinal chemistry letters 21: 2670–2674. 30. Tschammer N, Elsner J, Goetz A, Ehrlich K, Schuster S, et al. (2011) Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. J Med Chem 54: 2477–2491. 31. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330: 1091–1095. 32. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, et al. (2011) Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol 7: 769–778. 33. Obiol-Pardo C, Lopez L, Pastor M, Selent J (2011) Progress in the structural prediction of G protein-coupled receptors: D3 receptor in complex with eticlopride. Proteins 79: 1695–1703. 34. Kortagere S, Cheng SY, Antonio T, Zhen J, Reith ME, et al. (2011) Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies. Biochemical pharmacology 81: 157–163. 35. Wang Q, Mach RH, Luedtke RR, Reichert DE (2010) Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. Journal of chemical information and modeling 50: 1970–1985. 36. Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195–201. 37. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T (2009) The SWISSMODEL Repository and associated resources. Nucleic Acids Res 37: D387–392. 38. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33–38, 27–38. 39. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781–1802. 40. Darden T YD, Pedersen L (1993) Particle mesh Ewald: An N [center-dot] log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089–10092. 41. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455–461. 42. Morris GM, Goodsell DS, Huey R, Olson AJ (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10: 293–304. 43. Huey R, Morris GM, Olson AJ, Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28: 1145–1152. 44. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2012) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 40: D13–25. 45. Irwin JJ, Shoichet BK (2005) ZINC–a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177–182. 46. Schuttelkopf AW, van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355–1363. 47. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, et al. (2011) Open Babel: An open chemical toolbox. J Cheminform 3: 33. 48. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, et al. (2001) Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. The Journal of biological chemistry 276: 29171–29177. 49. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, et al. (2004) The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. Journal of molecular biology 342: 571–583.
PLOS ONE | www.plosone.org
11
September 2012 | Volume 7 | Issue 9 | e44316
D2 and D3 Receptors Modeling
50. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289: 739– 745. 51. Vogel R, Mahalingam M, Ludeke S, Huber T, Siebert F, et al. (2008) Functional role of the ‘‘ionic lock’’–an interhelical hydrogen-bond network in family A heptahelical receptors. Journal of molecular biology 380: 648–655. 52. Le Guilloux V, Schmidtke P, Tuffery P (2009) Fpocket: an open source platform for ligand pocket detection. BMC bioinformatics 10: 168. 53. Yap BK, Buckle MJ, Doughty SW (2012) Homology modeling of the human 5HT(1A), 5-HT (2A), D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation. Journal of molecular modeling. 54. Lape M, Elam C, Paula S (2010) Comparison of current docking tools for the simulation of inhibitor binding by the transmembrane domain of the sarco/ endoplasmic reticulum calcium ATPase. Biophys Chem 150: 88–97. 55. Yap BK, Buckle MJ, Doughty SW (2012) Homology modeling of the human 5HT(1A), 5-HT (2A), D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation. J Mol Model. 56. Kuzhikandathil EV, Kortagere S (2012) Identification and Characterization of a Novel Class of Atypical Dopamine Receptor Agonists. Pharmaceutical research. 57. Ghosh B, Antonio T, Zhen J, Kharkar P, Reith ME, et al. (2010) Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydro benzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson’s disease animal models. J Med Chem 53: 1023–1037. 58. Zhang J, Zhang Y (2010) GPCRRD: G protein-coupled receptor spatial restraint database for 3D structure modeling and function annotation. Bioinformatics 26: 3004–3005.
59. Zhang J, Liang Y, Zhang Y (2011) Atomic-level protein structure refinement using fragment-guided molecular dynamics conformation sampling. Structure 19: 1784–1795. 60. Wang Q, Mach RH, Luedtke RR, Reichert DE (2010) Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. J Chem Inf Model 50: 1970–1985. 61. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, et al. (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35: 79–95. 62. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, et al. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. The Journal of pharmacology and experimental therapeutics 303: 791–804. 63. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn-Schmiedeberg’s archives of pharmacology 379: 73–86. 64. Sokoloff P, Andrieux M, Besancon R, Pilon C, Martres MP, et al. (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. European journal of pharmacology 225: 331–337. 65. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2011) Functional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptors. European journal of pharmacology 666: 43–52. 66. Scheideler MA, Martin J, Hohlweg R, Rasmussen JS, Naerum L, et al. (1997) The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain. European journal of pharmacology 339: 261–270.
PLOS ONE | www.plosone.org
12
September 2012 | Volume 7 | Issue 9 | e44316
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • Docking Essay
  • Cross-Docking Essay
  • cross docking Essay
  • Design, Synthesis and Docking Studies of a Novel Essay
  • Cross Docking Essay
  • Essay on Cross Docking
  • cross docking Essay
  • Cross-Docking: State of the Art Essay

Become a StudyMode Member

Sign Up - It's Free